Viewing data from:

CEFAZOLIN SODIUM

ANDA

CEFAZOLIN SODIUM | A203661 | QILU ANTIBIOTICS PHARMACEUTICAL CO LTD

3 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 2 NDCs

Highest NADAC/Unit

$0.9884

per ea

Lowest NADAC/Unit

$0.9884

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
60505614205CEFAZOLIN 1 GM VIAL	$0.9884	EA	Generic	—	2026-06-17
60505624304CEFAZOLIN 1 GM VIAL	$0.9884	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain4 active DMFs12 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

ACS DOBFAR SPACEFAZOLIN SODIUM LYOPHILIZED (STERILE, BULK)

DMF 132081998

SANDOZ GMBHCEFAZOLIN SODIUM (STERILE)

DMF 141331999

ORCHID PHARMA LTDCEFAZOLIN USP

DMF 150222000

ORCHID PHARMA LTDCEFAZOLIN SODIUM, USP (STERILE BULK)

DMF 161342002

HOECHST AGInactiveCEFAZOLIN SODIUM INJECTION (STERILE FILLING)

DMF 67841987

GEMA SAInactiveCEFAZOLIN

DMF 81371989

BIOCHEMIC GESELLSCHAFT MBHInactiveCEFAZOLIN

DMF 86341990

BIOCHIMICA OPOS 2 SPAInactiveCEFAZOLIN SODIUM, BULK

DMF 101301986

ASTELLAS PHARMA INCInactiveCEFAZOLIN

DMF 101561991

ACS DOBFAR SPAInactiveCEFAZOLIN SODIUM

DMF 136901998

BRISTOL MYERS SQUIBB COInactiveCEFAZOLIN SODIUM

DMF 137071998

BRISTOL MYERS SQUIBB COInactiveCEFAZOLIN SODIUM

DMF 137501998

TEVA PHARMACEUTICALS USA INCInactiveCEFAZOLIN SODIUM

DMF 137411998

ASTELLAS PHARMA INCInactiveCEFAZOLIN SODIUM (STERILE)

DMF 137971998

AUROBINDO PHARMA LTDInactiveCEFAZOLIN SODIUM USP

DMF 183862005

CSPC ZHONGNUO PHARMACEUTICAL SHIJIAZHUANG CO LTDInactiveCEFAZOLIN SODIUM (STERILE)

DMF 245272011

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (3)

Sort:

#001 — EQ 1GM BASE/VIAL

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Dec 28, 2015

No patent or exclusivity listings for this strength.

#002 — EQ 2GM BASE/VIAL

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Mar 11, 2022

#003 — EQ 3GM BASE/VIAL

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Jan 24, 2024